We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to ...

Piper Sandler downgraded Biogen (NASDAQ:BIIB) to neutral from overweight on Thursday, citing, among other things, the company ...

BIIB is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 9.31; value investors ...

Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new ...

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (SNSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.

Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a significant decrease in short interest in the month of ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by research analysts at Piper Sandler from an “overweight” rating to a “neutral” rating in a research report issued on Thursday ...

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have received an average rating of “Hold” from the twenty-nine ...

If we look at 2024’s biggest loser on the Nasdaq 100, it becomes clear that even the mightiest can stumble. The name is Intel ...

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...

Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (BRSE:BIIB) from Overweight to Neutral. There are 1,768 funds or institutions reporting positions in Biogen.